Merck Serono to invest €65 million for Biopharmaceutical R&D facility expansion in Germany


Merck Serono, the biopharmaceutical business of Merck, announced the expansion of its R&D facility in Darmstadt, Germany with an investment of €65 million.


Merck is investing €65 million in a new laboratory building that will span more than 16,000 square meters and accommodate approximately 200 current employees whose focus will be accelerating innovation in R&D.

The new building will unite different functions within R&D Discovery Technologies at Merck Serono, including Molecular Pharmacology, Medicinal Chemistry, Computational Chemistry, Molecular Interactions and Biophysics, Protein Engineering and Antibody Technologies, and Protein and Cell Sciences.

With approximately 2,000 scientific and clinical development professionals working across four R&D hubs – Darmstadt, Germany, the largest R&D site; Boston, US; Tokyo, Japan; and Beijing, China – Merck Serono endeavors to make a meaningful difference in the lives of people with serious medical needs. The core areas of R&D focus for Merck Serono are oncology, immuno-oncology, and immunology.


Company Name Merck Serono
Location Darmstadt, Germany
Type R&D Facility Expansion
Estimated Cost €65 million
Laboratory Building Completion Fall Of 2017
share on: